Head-To-Head Comparison: Alnylam Pharmaceuticals (NASDAQ:ALNY) and Briacell Therap (NASDAQ:BCTX)

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Briacell Therap (NASDAQ:BCTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Alnylam Pharmaceuticals and Briacell Therap, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1	3	23	0	2.81
Briacell Therap	1	0	1	0	2.00

Alnylam Pharmaceuticals currently has a consensus target price of $466.92, indicating a potential downside of 3.05%. Briacell Therap has a consensus target price of $320.00, indicating a potential upside of 2,472.35%. Given Briacell Therap’s higher possible upside, analysts clearly believe Briacell Therap is more favorable than Alnylam Pharmaceuticals.

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and Briacell Therap”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.25 billion	28.08	-$278.16 million	($2.47)	-194.98
Briacell Therap	N/A	N/A	-$26.31 million	($83.18)	-0.15

Briacell Therap has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alnylam Pharmaceuticals and Briacell Therap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-12.96%	-273.52%	-7.39%
Briacell Therap	N/A	-291.42%	-180.62%

Volatility & Risk

Alnylam Pharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.

Insider and Institutional Ownership

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Briacell Therap shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Briacell Therap on 7 of the 13 factors compared between the two stocks.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.